

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07K 1/18, 14/605, 14/62	A1	(11) International Publication Number: WO 00/55184 (43) International Publication Date: 21 September 2000 (21.09.00)
(21) International Application Number: PCT/DK00/00112 (22) International Filing Date: 15 March 2000 (15.03.00) (30) Priority Data: PA 1999 00360 15 March 1999 (15.03.99) DK PA 2000 00083 19 January 2000 (19.01.00) DK (71) Applicant: NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsvaerd (DK). (72) Inventor: STABY, Arne; Gunnarsvej 17, DK-2880 Bagsvaerd (DK).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: ION EXCHANGE CHROMATOGRAPHY OF PROTEINS AND PEPTIDES WITH AN ORGANIC MODIFIER IN THE ELUTION STEP (57) Abstract The present invention relates to an ion exchange chromatography process for purifying a peptide from a mixture containing said peptide and related impurities, and to an industrial method including such ion exchange chromatography process. The elution step is performed with a solution comprising an organic modifier, e.g. alcohols, alkanolic acids, urea, guanidine, polyalcohols etc. The aqueous elution medium supports a net charge distribution on the protein or peptide that differs from the net charge of the impurities.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

ION EXCHANGE CHROMATOGRAPHY OF PROTEINS AND PEPTIDES WITH AN ORGANIC MODIFIER IN THE ELUTION STEP

Field of the invention

The present invention relates to an ion exchange chromatography process for purifying a peptide from a mixture containing said peptide and related impurities, and to an industrial method including such ion exchange chromatography process.

Background

For the purification and analysis of proteins and peptides, chromatography is a well-known and widely used method. A number of different chromatographic principles are applied, among these ion exchange chromatography (IEC). The IEC principle includes two different approaches: anion exchange and cation exchange according to the charge of the ligands on the ion exchange resin. A conventional IEC purification process usually consists of one or more: equilibration sections, application or loading sections, wash sections, elution sections, and regeneration sections (cf. Remington's Pharmaceutical Sciences, Gennaro, ed., Mack Publishing Co., Easton, PA, 1990, or Remington: The Science and Practice of Pharmacy, 19th Edition (1995)).

The main principle of elution in IEC in industrial purification processes is salt component gradients in an aqueous buffer solution at constant pH, either as step or linear gradients (cf. S. Bjørn and L. Thim, Activation of Coagulation Factor VII to VIIa, Res. Discl. No. 269, 564-565, 1986). Isocratic elution is possible, but seldom used. Organic solvents or modifiers have occasionally been added to the solutions to keep the protein or peptide on the desired form or just in solution (cf. K. H. Jørgensen, Process for Purifying Insulin, US Patent No. 3,907,676, Sept. 23, 1975; and J. Brange, O. Hallund and E. Sørensen, Chemical Stability of Insulin 5. Isolation, Characterisation and Identification of Insulin Transformation Products, Acta Pharm. Nord. 4(4), 223-232, 1992). Also, the change in pH may occasionally be employed to elute the target protein (cf. J. Lamy, J. Lamy, J. Weill, Arch. Biochem. Biophys. 193, 140-149, 1979).

Description of the invention

In contrast to the above described IEC techniques for purification of any protein or peptide, consisting of one or more equilibration steps, application or loading steps, wash steps, elution steps, and regeneration steps, the present invention relates to a novel elution technique which is the combination of elution in a solution comprising an organic modifier with the subsequent elution in an aqueous solution at the same or a different pH optionally

followed by a regeneration step. The equilibration solution and the sample for application may or may not contain the organic modifier. The elution of the peptide occurs at non-denaturing conditions (in a solution free of organic modifier). Moreover, the elution of the peptide is performed in a single peak.

- 5 Accordingly, in a broad aspect the present invention relates to a cation exchange chromatography process for purifying a peptide from a mixture comprising said peptide and related impurities, comprising the steps of:
- a) eluting said related impurities of said mixture in a solution comprising an organic modifier, water, optionally a salt component and optionally a buffer, at a linear or step gradient or is-
 - 10 ocratically in salt component, and at pH-values optionally maintained with a buffer so that said peptide has a positive local or overall net charge and said related impurities have a local or overall positive net charge which is lower than the positive net charge of said peptide so as to remove said related impurities,
 - b) subsequently, eluting said peptide by a step or linear change to an aqueous solvent op-
 - 15 tionally with a salt component, at the same or higher pH-values optionally maintained with a buffer.

In another broad aspect the present invention relates to a cation exchange chromatography process for purifying a peptide from a mixture comprising said peptide and related impurities, comprising the steps of:

- 20 a) eluting said related impurities of said mixture in a solution consisting essentially of an organic modifier, water, optionally a salt component and optionally a buffer, at a linear or step gradient or isocratically in salt component, and at pH-values optionally maintained with a buffer so that said peptide has a positive local or overall net charge and said related impurities have a local or overall positive net charge which is lower than the positive net charge of
- 25 said peptide so as to remove said related impurities,
- b) subsequently, eluting said peptide by a step or linear change to an aqueous solvent optionally with a salt component, at the same or higher pH-values optionally maintained with a buffer.

In another broad aspect the present invention relates to an anion exchange chromatography process for purifying a peptide from a mixture comprising said peptide and related impurities, comprising the steps of:

- 30 a) eluting said related impurities of said mixture in a solution comprising an organic modifier, water, optionally a salt component and optionally a buffer, at a linear or step gradient or isocratically in salt component, and at pH-values optionally maintained with a buffer so that

said peptide has a negative local or overall net charge and said related impurities have a local or overall negative net charge which is lower than the negative net charge of said peptide so as to remove said related impurities,

- 5 b) subsequently, eluting said peptide by a step or linear change to an aqueous solvent optionally with a salt component, at the same or lower pH-values optionally maintained with a buffer.

In another broad aspect the present invention relates to an anion exchange chromatography process for purifying a peptide from a mixture comprising said peptide and related impurities, comprising the steps of:

- 10 a) eluting said related impurities of said mixture in a solution consisting essentially of an organic modifier, water, optionally a salt component and optionally a buffer, at a linear or step gradient or isocratically in salt component, and at pH-values optionally maintained with a buffer so that said peptide has a negative local or overall net charge and said related impurities have a local or overall negative net charge which is lower than the negative net charge
15 of said peptide so as to remove said related impurities,
b) subsequently, eluting said peptide by a step or linear change to an aqueous solvent optionally with a salt component, at the same or lower pH-values optionally maintained with a buffer.

- 20 In the above aspects of the present process the elution in step a) could also be considered a washing step of related impurities.

The elution of the peptide in step b) occurs at non-denaturing conditions (in a solution free of organic modifier). Thus, the peptide is eluted to an aqueous solution with a solution comprising water and optionally a salt component, an acid or base, and/or a buffer, but without the presence of an organic modifier.

- 25 In one embodiment of the present invention the ratio of organic modifier to water, on a weight percent basis, is from 1:99 to 99:1, such as from 1:99 to 80:20, 20:80 to 80:20, 30:70 to 70:30, 35:50 to 50:35, or 40:50 to 50:40. Each of these ranges constitutes an alternative embodiment of the present invention.

- 30 In further embodiments of the present invention the organic modifier is selected from C₁₋₆-alkanol, C₁₋₆-alkenol or C₁₋₆-alkynol, urea, guanidine, or C₁₋₆-alkanoic acid, such as acetic acid, C₂₋₆-glycol, C₃₋₇-polyalcohol including sugars, preferably C₁₋₆-alkanol and C₂₋₆-glycol, more preferably methanol, ethanol, propanols and butanols and hexyl glycols, most preferably ethanol and 2-propanol. Each of these organic modifiers constitutes an alternative embodiment of the present invention.

In a further embodiment of the present invention the salt component in step a) is selected from any organic or inorganic salt and mixtures thereof, preferably NaCl, KCl, NH_4Cl , CaCl_2 , sodium acetate, potassium acetate, ammonium acetate, sodium citrate, potassium citrate, ammonium citrate, sodium sulphate, potassium sulphate, ammonium sulphate, calcium acetate or mixtures thereof, most preferred sodium acetate, potassium acetate, ammonium acetate, NaCl, NH_4Cl , KCl. Each of these salt components constitutes an alternative embodiment of the present invention.

In a further embodiment of the present invention the gradient in salt component in step a) is a step gradient in the salt component.

In a further embodiment of the present invention the salt component in step a) is present in a step concentration selected from the range of 0.1 mmol/kg to 3000 mmol/kg, preferably 1 mmol/kg to 1000 mmol/kg, more preferably 5 mmol/kg to 500, most preferably 20 mmol/kg to 300 mmol/kg. Each of these ranges constitutes an alternative embodiment of the present invention.

In a further embodiment of the present invention the salt component gradient in step a) is a linear gradient in salt component.

In a further embodiment of the present invention the salt component in step a) is present in a linear concentration selected from 0.1 mmol/kg to 3000 mmol/kg, preferably 1 mmol/kg to 1000 mmol/kg, more preferably 5 mmol/kg to 500, most preferably 20 mmol/kg to 300 mmol/kg. Each of these linear concentrations constitutes an alternative embodiment of the present invention.

In a further embodiment of the present invention no salt component is present in step a).

In a further embodiment of the present invention the salt component in step b) is selected from any organic or inorganic salt, preferably NaCl, KCl, NH_4Cl , CaCl_2 , sodium acetate, potassium acetate, ammonium acetate, sodium citrate, potassium citrate, ammonium citrate, sodium sulphate, potassium sulphate, ammonium sulphate, calcium acetate or mixtures thereof, most preferred sodium acetate, potassium acetate, ammonium acetate, NaCl, NH_4Cl , KCl. Each of these salt components constitutes an alternative embodiment of the present invention.

In a further embodiment of the present invention the salt component in step b) is present in a concentration selected from the range of 0.1 mmol/kg to 3000 mmol/kg, preferably 1 mmol/kg to 1000 mmol/kg, more preferably 5 mmol/kg to 500, most preferably 20

mmol/kg to 300 mmol/kg. Each of these ranges constitutes an alternative embodiment of the present invention.

In a further embodiment of the present invention no salt component is present in step b).

5 In a further embodiment of the present invention the buffer in step a) or b) is independently selected from citrate buffers, phosphate buffers, tris buffers, borate buffers, lactate buffers, glycyl glycin buffers, arginine buffers, carbonate buffers, acetate buffers, glutamate buffers, ammonium buffers, glycine buffers, alkylamine buffers, aminoethyl alcohol buffers, ethylenediamine buffers, tri-ethanol amine, imidazole buffers, pyridine buffers and barbiturate buffers and mixtures thereof, preferably citric acid, sodium citrate, sodium phosphate, 10 phosphoric acid, glutamic acid, sodium glutamate, glycine, sodium carbonate, potassium citrate, potassium phosphate, potassium glutamate, potassium carbonate, tris-hydroxymethyl amino methane and boric acid and mixtures thereof. Each of these buffers constitutes an alternative embodiment of the present invention.

15 In a further embodiment of the present invention the buffer in step a) is present in a concentration selected from the range of 0.1 mmol/kg to 500 mmol/kg, preferably 1 mmol/kg to 200 mmol/kg, more preferably 5 mmol/kg to 100 mmol/kg, most preferably 10 mmol/kg to 50 mmol/kg. Each of these ranges constitutes an alternative embodiment of the present invention.

20 In a further embodiment of the present invention the buffer in step b) is present in a concentration selected from the range of 0.1 mmol/kg to 1000 mmol/kg, preferably 1 mmol/kg to 400 mmol/kg, most preferably 50 mmol/kg to 200 mmol/kg. Each of these ranges constitutes an alternative embodiment of the present invention.

In a further embodiment of the present invention no buffer is present in step a).

25 In a further embodiment of the present invention no buffer is present in step b).

In a further embodiment of the present invention the peptide to be purified is selected from polypeptides, oligopeptides, proteins, receptors, vira, as well as homologues, analogues and derivatives thereof, preferably glucagon, hGH, insulin, aprotinin, FactorVII, TPA, FactorVIIa, FFR-FactorVIIa, heparinase, ACTH, Heparin Binding Protein, corticotropin-releasing factor, angiotensin, calcitonin, insulin, glucagon-like peptide-1, glucagon-like peptide- 30 2, insulin-like growth factor-1, insulin-like growth factor-2, fibroblast growth factors, gastric inhibitory peptide, growth hormone-releasing factor, pituitary adenylate cyclase activating peptide, secretin, enterogastrin, somatostatin, somatotropin, somatomedin, parathyroid hormone, thrombopoietin, erythropoietin, hypothalamic releasing factors, prolactin, thyroid stimulating

hormones, endorphins, enkephalins, vasopressin, oxytocin, opioids, DPP IV, interleukins, immunoglobulins, complement inhibitors, serpin protease inhibitors, cytokines, cytokine receptors, PDGF, tumor necrosis factors, tumor necrosis factors receptors, growth factors and analogues as well as derivatives thereof, more preferably glucagon, hGH, insulin, aprotinin, FactorVII, FactorVIIa, FFR-FactorVIIa, heparinase, glucagon-like peptide-1, glucagon-like peptide-2 and analogues as well as derivatives thereof, such as Val⁸GLP-1(7-37), Thr⁸GLP-1(7-37), Met⁸GLP-1(7-37), Gly⁸GLP-1(7-37), Val⁸GLP-1(7-36) amide, Thr⁸GLP-1(7-36) amide, Met⁸GLP-1(7-36) amide, Gly⁸GLP-1(7-36) amide, Arg³⁴GLP-1₍₇₋₃₇₎, human insulin, and B28IsoAsp insulin. Each of these peptides constitutes an alternative embodiment of the present invention.

As an example illustrating the present invention, histidine has a predominant positive net charge below pH~6.5, thus for cation exchange the wash or elution section with organic solvent or modifier could be performed below pH 6.5 to remove a truncated form missing histidine, and subsequent elution of the target protein or peptide in the aqueous solvent could be performed above pH 6.5. As a second example, the carboxyl group of the C-terminal amino acid has a predominant negative net charge above pH~3.1, thus for anion exchange the wash or elution section with organic solvent could be performed above pH 3.1 to remove a form extended to an amide, and subsequent elution of the target protein or peptide in the aqueous solvent could be performed both above or below pH 3.1. As a third example, aspartic acid has a predominant negative net charge above pH~4.4, thus for anion exchange the wash or elution section with organic solvent could be performed above pH 4.4 to remove a truncated form missing aspartic acid, and subsequent elution of the target protein or peptide in the aqueous solvent could be performed below pH 4.4. As a fourth example, glutamic acid has a predominant negative net charge above pH~4.4, thus for anion exchange the wash or elution section with organic solvent could be performed above pH 4.4 to remove a truncated form missing glutamic acid, and subsequent elution of the target protein or peptide in the aqueous solvent could be performed below pH 4.4. As a fifth example, γ -carboxy glutamic acid has a predominant negative net charge above pH~4.4, thus for anion exchange the wash or elution section with organic solvent could be performed above pH 4.4 to remove a form missing one or more γ -carboxy groups of specific glutamic acid residues, and subsequent elution of the target protein or peptide in the aqueous solvent could be performed below pH 4.4. As a sixth example, the amino group of the N-terminal amino acid has a predominant positive net charge below pH~8.0, thus for cation exchange the wash or elution section with organic solvent could be performed below pH 8.0 to remove a form ex-

tended with an acyl group, and subsequent elution of the target protein or peptide in the aqueous solvent could be performed both above or below pH 8.0. As a seventh example, cysteine has a predominant negative net charge above pH~8.5, thus for anion exchange the wash or elution section with organic solvent could be performed above pH 8.5 to remove a poorly folded form resulting in free cysteine residues, and subsequent elution of the target protein or peptide in the aqueous solvent could be performed below pH 8.5. As an eighth example, tyrosine has a predominant negative net charge above pH~10.0, thus for anion exchange the wash or elution section with organic solvent could be performed above pH 10.0 to remove a truncated form missing a tyrosine residue, and subsequent elution of the target protein or peptide in the aqueous solvent could be performed below pH 10.0. As a ninth example, lysine has a predominant positive net charge below pH~10.0, thus for cation exchange the wash or elution section with organic solvent could be performed below pH 10.0 to remove a form acylated in the side chain of the lysine residue, and subsequent elution of the target protein or peptide in the aqueous solvent could be performed above or below pH 10.0. As a tenth example, arginine has a predominant positive net charge below pH~12.0, thus for anion exchange the wash or elution section with organic solvent could be performed below pH 12.0 to remove a truncated form missing an arginine residue, and subsequent elution of the target protein or peptide in the aqueous solvent could be performed above pH 12.0. (pK_A-values used in these examples are from: L. Stryer. Biochemistry, 3rd edition, W. H. Freeman and Company, New York, Table 2-1 page 21).

Specific peptide examples of the above-mentioned method are separation of Arg³⁴GLP-1₍₇₋₃₇₎ and Arg³⁴GLP-1₍₉₋₃₇₎ by cation exchange chromatography, human insulin and B30 human insulin ethyl ester by anion exchange chromatography, B28IsoAsp insulin and DesB23-30 insulin by anion exchange chromatography, prothrombin and des-γ-carboxy-Glu prothrombin by anion exchange chromatography, Arg³⁴GLP-1₍₇₋₃₇₎ and Arg³⁴GLP-1₍₁₀₋₃₇₎ by anion exchange chromatography, Lys^{B29}-(N-ε(α-tetradecanoyl))-desB30 insulin and DesB30 insulin by cation exchange chromatography, Lys^{B29}-(N-ε(α-tetradecanoyl))-desB30 insulin and Lys^{B29}-(N-ε(α-tetradecanoyl))-A1-(N-ε(α-tetradecanoyl))-desB30 insulin by cation exchange chromatography, aprotinin and Des-Arg-Pro-aptinin by cation exchange chromatography, and Glucagon₍₁₋₂₉₎ and Glucagon₍₆₋₂₉₎ by anion exchange chromatography.

The peptides can be produced by a method which comprises culturing or fermenting a host cell containing a DNA sequence encoding the polypeptide and capable of expressing the polypeptide in a suitable nutrient medium under conditions permitting the expression of the

peptide, after which the resulting peptide is recovered from the culture or fermentation broth. Hereinafter, culturing will be used to cover both culturing and fermenting and the like.

The medium used to culture the cells may be any conventional medium suitable for growing the host cells, such as minimal or complex media containing appropriate supplements.

5 Suitable media are available from commercial suppliers or may be prepared according to published recipes (e.g. in catalogues of the American Type Culture Collection). The peptide produced by the cells may then be recovered from the culture medium by conventional procedures including, optionally lysis of cells, separating the host cells from the medium by centrifugation or filtration, precipitating the proteinaceous components of the supernatant or
10 filtrate by means of a salt, e.g. ammonium sulphate, purification by conventional purification techniques, such as chromatographic techniques, if necessary, purification by ion exchange chromatography according to the present invention, and subsequently, subjecting to analytical tests, e.g. PAGE, IEF, if necessary, subjecting to further purification, if necessary, and isolation of the pure peptide.

15 During the recovery of the resulting peptide from the culture medium, but before purification by ion exchange chromatography according to the present invention, the mixture comprising the peptide and related impurities may optionally be chemically modified by conventional techniques, e.g. by alkylation, acylation, ester formation or amide formation or the like.

20 The DNA sequence encoding the parent peptide may suitably be of genomic or cDNA origin, for instance obtained by preparing a genomic or cDNA library and screening for DNA sequences coding for all or part of the peptide by hybridisation using synthetic oligonucleotide probes in accordance with standard techniques (see, for example, Sambrook, J, Fritsch, EF and Maniatis, T, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory
25 Press, New York, 1989). The DNA sequence encoding the peptide may also be prepared synthetically by established standard methods, e.g. the phosphoramidite method described by Beaucage and Caruthers, *Tetrahedron Letters* 22 (1981), 1859 - 1869, or the method described by Matthes *et al.*, *EMBO Journal* 3 (1984), 801 - 805. The DNA sequence may also be prepared by polymerase chain reaction using specific primers, for instance as described in
30 US 4,683,202 or Saiki *et al.*, *Science* 239 (1988), 487 - 491.

The DNA sequence may be inserted into any vector which may conveniently be subjected to recombinant DNA procedures, and the choice of vector will often depend on the host cell into which it is to be introduced. Thus, the vector may be an autonomously replicating vector, i.e. a vector which exists as an extrachromosomal entity, the replication of which is

independent of chromosomal replication, e.g. a plasmid. Alternatively, the vector may be one which, when introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome(s) into which it has been integrated.

5 The vector is preferably an expression vector in which the DNA sequence encoding the peptide is operably linked to additional segments required for transcription of the DNA, such as a promoter. The promoter may be any DNA sequence which shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell. Examples of suitable promoters for directing the transcription of the DNA encoding the peptide of the invention in a variety of host cells are well known in the art, cf. for instance Sambrook *et al.*, *supra*.
10

The DNA sequence encoding the peptide may also, if necessary, be operably connected to a suitable terminator, polyadenylation signals, transcriptional enhancer sequences, and translational enhancer sequences. The recombinant vector of the invention may further comprise a DNA sequence enabling the vector to replicate in the host cell in question.
15

The vector may also comprise a selectable marker, e.g. a gene the product of which complements a defect in the host cell or one which confers resistance to a drug, e.g. ampicillin, kanamycin, tetracyclin, chloramphenicol, neomycin, hygromycin or methotrexate.

To direct a peptide into the secretory pathway of the host cells, a secretory signal sequence (also known as a leader sequence, prepro sequence or pre sequence) may be provided in the recombinant vector. The secretory signal sequence is joined to the DNA sequence encoding the peptide in the correct reading frame. Secretory signal sequences are commonly positioned 5' to the DNA sequence encoding the peptide. The secretory signal sequence may be that normally associated with the peptide or may be from a gene encoding another secreted protein.
20
25

The procedures used to ligate the DNA sequences coding for the peptide, the promoter and optionally the terminator and/or secretory signal sequence, respectively, and to insert them into suitable vectors containing the information necessary for replication, are well known to persons skilled in the art (cf., for instance, Sambrook *et al.*, *supra*):

30 The host cell into which the DNA sequence or the recombinant vector is introduced may be any cell which is capable of producing the present peptide and includes bacteria, vira, e.g. baculo virus, yeast, fungi, insect cells and higher eukaryotic cells. Examples of suitable host cells well known and used in the art are, without limitation, *E. coli*, *Saccharomyces cerevisiae*, or mammalian BHK or CHO cell lines.

Some of the peptides, in particular the oligopeptides, can be produced according to conventional organic peptide synthetic chemistry. The resulting synthetic mixture may then be chemically modified, e.g. by alkylation, acylation, ester formation or amide formation or the like, and purified, or purified as it is and then modified chemically as mentioned above.

5 Preparation of Factor VIIa

Human purified factor VIIa suitable for use in the present invention is preferably made by DNA recombinant technology, e.g. as described by Hagen et al., Proc.Natl.Acad.Sci. USA 83: 2412-2416, 1986 or as described in European Patent No. 200.421 (ZymoGenetics). Factor VIIa produced by recombinant technology may be authentic factor VIIa or a more or less modified factor VIIa provided that such factor VIIa has substantially the same biological activity for blood coagulation as authentic factor VIIa. Such modified factor VIIa may be produced by modifying the nucleic acid sequence encoding factor VII either by altering the amino acid codons or by removal of some of the amino acid codons in the nucleic acid encoding the natural FVII by known means, e.g. by site-specific mutagenesis.

Factor VII may also be produced by the methods described by Broze and Majerus, J.Biol.Chem. 255 (4): 1242-1247, 1980 and Hedner and Kisiel, J.Clin.Invest. 71: 1836-1841, 1983. These methods yield factor VII without detectable amounts of other blood coagulation factors. An even further purified factor VII preparation may be obtained by including an additional gel filtration as the final purification step. Factor VII is then converted into activated FVIIa by known means, e.g. by several different plasma proteins, such as factor XIIa, IX a or Xa. Alternatively, as described by Bjoern et al. (Research Disclosure, 269 September 1986, pp. 564-565), factor VII may be activated by passing it through an ion-exchange chromatography column, such as Mono Q® (Pharmacia fine Chemicals) or the like.

25 Modified or inactivated FVIIa (FVIIai) may be produced by the following methods:

International Application No. WO 92/15686 relates to modified Factor VIIa, polynucleic acid and mammalian cell lines for the production of modified Factor VIIa, and compositions comprising modified Factor VIIa for inhibiting blood coagulation.

Modified Factor VII may be encoded by a polynucleotide molecule comprising two operatively linked sequence coding regions encoding, respectively, a pre-pro peptide and a gla domain of a vitamin K-dependent plasma protein, and a gla domain-less Factor VII protein, wherein upon expression said polynucleotide encodes a modified Factor VII molecule which does not significantly activate plasma Factors X or IX, and is capable of binding tissue factor.

The catalytic activity of Factor VIIa can be inhibited by chemical derivatization of the catalytic centre, or triad. Derivatization may be accomplished by reacting Factor VII with an irreversible inhibitor such as an organophosphor compound, a sulfonyl fluoride, a peptide halomethyl ketone or an azapeptide, or by acylation, for example. Preferred peptide
5 halomethyl ketones include PPACK (D-Phe-Pro-Arg chloromethyl-ketone; (see U.S. Patent No. 4,318,904, incorporated herein by reference), D-Phe-Phe-Arg and Phe-Phe-Arg chloromethylketone (FFR-cmk); and DEGRck (dansyl-Glu-Gly-Arg chloromethylketone).

The catalytic activity of Factor VIIa can also be inhibited by substituting, inserting or deleting amino acids. In preferred embodiments amino acid substitutions are made in the
10 amino acid sequence of the Factor VII catalytic triad, defined herein as the regions, which contain the amino acids, which contribute to the Factor VIIa catalytic site. The substitutions, insertions or deletions in the catalytic triad are generally at or adjacent to the amino acids which form the catalytic site. In the human and bovine Factor VII proteins, the amino acids, which form a catalytic "triad", are Ser₃₄₄, Asp₂₄₂, and His₁₉₃ (subscript numbering indicating
15 position in the sequence). The catalytic sites in Factor VII from other mammalian species may be determined using presently available techniques including, among others, protein isolation and amino acid sequence analysis. Catalytic sites may also be determined by aligning a sequence with the sequence of other serine proteases, particularly chymotrypsin, whose active site has been previously determined (Sigler et al., *J. Mol. Biol.*, 35:143-164
20 (1968), incorporated herein by reference), and there from determining from said alignment the analogous active site residues.

In preferred embodiments of human and bovine Factor VII, the active site residue Ser₃₄₄ is modified, replaced with Gly, Met, Thr, or more preferably, Ala. Such substitution could be made separately or in combination with substitution(s) at other sites in the catalytic
25 triad, which includes His₁₉₃ and Asp₂₄₂.

The amino acids, which form the catalytic site in Factor VII, such as Ser₃₄₄, Asp₂₄₂, and His₁₉₃ in human and bovine Factor VII, may either be substituted or deleted. Within the present invention, it is preferred to change only a single amino acid, thus minimizing the likelihood of increasing the antigenicity of the molecule or inhibiting its ability to bind tissue
30 factor, however two or more amino acid changes (substitutions, additions or deletions) may be made and combinations of substitution(s), addition(s) and deletion(s) may also be made. In a preferred embodiment for human and bovine Factor VII, Ser₃₄₄ is preferably substituted with Ala, but Gly, Met, Thr or other amino acids can be substituted. It is preferred to replace Asp with Glu and to replace His with Lys or Arg. In general, substitutions are chosen to

disrupt the tertiary protein structure as little as possible. The model of Dayhoff et al. (in Atlas of Protein Structure 1978, Nat'l Biomed. Res. Found., Washington, D.C.), incorporated herein by reference, may be used as a guide in selecting other amino acid substitutions.

One may introduce residue alterations as described above in the catalytic site of appropriate

- 5 Factor VII sequence of human, bovine or other species and test the resulting protein for a desired level of inhibition of catalytic activity and resulting anticoagulant activity as described herein. For the modified Factor VII the catalytic activity will be substantially inhibited, generally less than about 5% of the catalytic activity of wild-type Factor VII of the corresponding species, more preferably less than about 1%.

- 10 The modified Factor VII may be produced through the use of recombinant DNA techniques.

The amino acid sequence alterations may be accomplished by a variety of techniques. Modification of the DNA sequence may be by site-specific mutagenesis.

- 15 Techniques for site-specific mutagenesis are well known in the art and are described by, for example, Zoller and Smith (DNA 3:479-488, 1984). Thus, using the nucleotide and amino acid sequences of Factor VII, one may introduce the alteration(s) of choice.

The modified FVIIa may also be produced by chemical methods.

FFR-FVIIa (that is, D-Phe-Phe-Arg-FVIIa)

- 20 EXAMPLE FFR chloromethyl ketone

Blockage of the active site of FVIIa with FFR chloromethyl ketone.

- Blockage of the active site serine and histidine with chloromethyl ketone is a well-known method for irreversible inactivation of serine proteases. In order to optimise the blockage of a given protease it is important to choose a chloromethyl ketone derivative, which reacts specifically with the active site and with a fast on-rate. Such derivatives can be developed by attachment to the chloromethyl ketone group of an oligopeptide, which interacts, with the substrate-binding pocket of the particular serine protease of interest.
- 25

- Glutamyl-Glycyl-Arginine chloromethyl ketone (EGR-ck or its Dansyl derivative, DEGR-ck) (S. Higashi, H. Nishimura, S. Fujii, K. Takada, S. Iwanaga, (1992) J. Biol. Chem. 267, 17990) or Prolyl-Phenyl-Arginine chloromethyl ketone (PFR-ck) (J. H. Lawson, S. Buentenas, K. Mann, (1992) J. Biol. Chem. 267, 4834; J. Contrino, G. A. Hair, M. A. Schmeizl, F. R. Rickles, D. L. Kreutzer (1994) Am. J. Pathol. 145, 1315) have been applied as active site inhibitors of FVIIa. Compared with these chloromethyl ketones application of FFRck represents a rate increase of 10 - 70 fold.
- 30

The specificity of the reaction with FFR-chloromethyl ketone derivative of FVIIa was checked by HPLC and peptide mapping which showed that FVIIa had reacted with FFR-chloromethyl ketone in a 1:1 ratio such that > 98% could be recovered as the expected product derivatized at histidine 193.

5

Inactivation of FVIIa by various chloromethyl ketones:

3 μ M FVIIa was incubated with 12 μ M of chloromethyl ketone derivative in 50 mM TrisHCl, 100 mM NaCl, 5 mM CaCl_2 , 0.01 % Tween-80, pH 7.4. Samples were withdrawn at various time intervals as indicated and diluted 20 times for activity measurements in 50 mM TrisHCl, 100 mM NaCl, 5 mM CaCl_2 , 0.01 % Tween-80, pH 7.4 containing 1 mM Ile-Pro-Arg-pNA. The residual FVIIa activity was measured by the increase in absorbance at 405 nm.

Usually, the mixture comprising the peptide and related impurities to be purified by ion exchange chromatography according to the present invention, will also contain amino acids, small peptides, large peptides, unrelated proteins, reactants, cell debris, HCP, endotoxins, and/or vira depending on whether recombinant DNA techniques and/or chemical modification techniques have been used or whether organic peptide synthetic chemistry techniques have been used.

Thus, any method, such as an industrial method, for producing a pure peptide, which includes an IEC process according to the present invention is also an aspect of the present application.

Accordingly, the present invention relates in a further aspect to an industrial method for producing a pure peptide, the method including a cation exchange chromatography process for purifying a peptide from a mixture comprising said peptide and related impurities, comprising the steps of:

- a) eluting said related impurities of said mixture in a solution consisting essentially of an organic modifier, water, optionally a salt component and optionally a buffer, at a linear or step gradient or isocratically in salt component, and at pH-values optionally maintained with a buffer so that said peptide has a positive local or overall net charge and said related impurities have a local or overall positive net charge which is lower than the positive net charge of said peptide so as to remove said related impurities,
- b) subsequently, eluting said peptide by a step or linear change to an aqueous solvent optionally with a salt component, at the same or higher pH-values optionally maintained with a buffer.

The present invention relates in a further aspect to a method for isolating a peptide, the method including purification of a peptide from a mixture comprising said peptide and related impurities via a cation exchange chromatography process, the cation exchange chromatography process comprising the steps of:

- a) eluting said related impurities of said mixture in a solution comprising an organic modifier, water, optionally a salt component and optionally a buffer, at a linear or step gradient or isocratically in salt component, and at pH-values optionally maintained with a buffer so that said peptide has a positive local or overall net charge and said related impurities have a local or overall positive net charge which is lower than the positive net charge of said peptide so as to remove said related impurities,
- b) subsequently, eluting said peptide by a step or linear change to an aqueous solvent optionally with a salt component, at the same or higher pH-values optionally maintained with a buffer;

and subsequently, if necessary, subjecting to analytical tests and/or further purification, and isolating said peptide in a conventional manner.

The present invention relates in a further aspect to a method for isolating a peptide, the method including purification of a peptide from a mixture comprising said peptide and related impurities via a cation exchange chromatography process, the cation exchange chromatography process comprising the steps of:

- a) eluting said related impurities of said mixture in a solution consisting essentially of an organic modifier, water, optionally a salt component and optionally a buffer, at a linear or step gradient or isocratically in salt component, and at pH-values optionally maintained with a buffer so that said peptide has a positive local or overall net charge and said related impurities have a local or overall positive net charge which is lower than the positive net charge of said peptide so as to remove said related impurities,
- b) subsequently, eluting said peptide by a step or linear change to an aqueous solvent optionally with a salt component, at the same or higher pH-values optionally maintained with a buffer;

and subsequently, if necessary, subjecting to analytical tests and/or further purification, and isolating said peptide in a conventional manner.

The present invention relates in a further aspect to an industrial method for producing a pure peptide, the method including an anion exchange chromatography process for

purifying a peptide from a mixture comprising said peptide and related impurities, comprising the steps of:

a) eluting said related impurities of said mixture in a solution consisting essentially of an organic modifier, water, optionally a salt component and optionally a buffer, at a linear or step
5 gradient or isocratically in salt component, and at pH-values optionally maintained with a buffer so that said peptide has a negative local or overall net charge and said related impurities have a local or overall negative net charge which is lower than the negative net charge of said peptide so as to remove said related impurities,

b) subsequently, eluting said peptide by a step or linear change to an aqueous solvent
10 optionally with a salt component, at the same or lower pH-values optionally maintained with a buffer.

The present invention relates in a still further aspect to a method for isolating a peptide, the method including purification of a peptide from a mixture comprising said peptide and related impurities via an anion exchange chromatography process, the anion exchange
15 chromatography process comprising the steps of:

a) eluting said related impurities of said mixture in a solution comprising an organic modifier, water, optionally a salt component and optionally a buffer, at a linear or step gradient or isocratically in salt component, and at pH-values optionally maintained with a buffer so that said peptide has a negative local or overall net charge
20 and said related impurities have a local or overall negative net charge which is lower than the negative net charge of said peptide so as to remove said related impurities,
b) subsequently, eluting said peptide by a step or linear change to an aqueous solvent optionally with a salt component, at the same or lower pH-values optionally maintained with a buffer;

25 and subsequently, if necessary, subjecting to analytical tests and/or further purification, and isolating said peptide in a conventional manner.

The present invention relates in a still further aspect to a method for isolating a peptide, the method including purification of a peptide from a mixture comprising said peptide and related impurities via an anion exchange chromatography process, the anion exchange
30 chromatography process comprising the steps of:

a) eluting said related impurities of said mixture in a solution consisting essentially of an organic modifier, water, optionally a salt component and optionally a buffer, at a linear or step gradient or isocratically in salt component, and at pH-values optionally maintained with a buffer so that said peptide has a negative local or overall net

charge and said related impurities have a local or overall negative net charge which is lower than the negative net charge of said peptide so as to remove said related impurities,

b) subsequently, eluting said peptide by a step or linear change to an aqueous solvent optionally with a salt component, at the same or lower pH-values optionally maintained with a buffer;

and subsequently, if necessary, subjecting to analytical tests and/or further purification, and isolating said peptide in a conventional manner.

Any possible combination of two or more of the embodiments described herein, is comprised within the scope of the present invention.

The term "an organic modifier", as used herein, is intended to include an organic solvent or organic compound soluble in water or mixtures thereof, which modifier induces a favorable and changed selectivity between the unwanted related impurity or impurities and the peptide and the ion exchanger. Whether or not a selected modifier induces said selectivity will usually depend on the related impurity or impurities, and may be tested by trial-and-error. The organic modifier includes but is not limited to C₁₋₆-alkanol, C₁₋₆-alkenol or C₁₋₆-alkynol, urea, guanidine-HCl, or C₁₋₆-alkanoic acid, such as acetic acid, C₂₋₆-glycol, C₃₋₇-polyalcohol including sugars or mixtures thereof.

The term "C₁₋₆-alkanol", "C₁₋₆-alkenol" or "C₁₋₆-alkynol", as used herein, alone or in combination is intended to include those C₁₋₆-alkane, C₁₋₆-alkene or C₁₋₆-alkyne groups of the designated length in either a linear or branched or cyclic configuration whereto is linked a hydroxyl (-OH) (cf. Morrison & Boyd, Organic Chemistry, 4th ed). Examples of linear alcohols are methanol, ethanol, n-propanol, allyl alcohol, n-butanol, n-pentanol and n-hexanol. Examples of branched alcohols are 2-propanol and tert-butyl alcohol. Examples of cyclic alcohols are cyclo propyl alcohol and 2-cyclohexen-1-ol.

The term "C₁₋₆-alkanoic acid", as used herein, is intended to include a group of the formula R'COOH wherein R' is H or C₁₋₅alkyl, such as acetic, propionic, butyric, methylbutyric, or valeric acid (cf. Morrison & Boyd, Organic Chemistry, 4th ed).

The term "C₁₋₅-alkyl", as used herein, is intended to include a branched or straight alkyl group having from one to five carbon atoms. Typical C₁₋₅-alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, butyl, iso-butyl, sec-butyl, tert-butyl, pentyl, iso-pentyl, and the like (cf. Morrison & Boyd, Organic Chemistry, 4th ed).

The term "C₂₋₆-glycol", as used herein, is intended to include a C₂₋₆-alkane containing two hydroxyl groups on different carbon atoms which may be adjacent or not. A typical C₂₋₆-glycol

include, but is not limited to 1,2-ethanediol, 1,2-propanediol, or 2-methyl-2,4-pentanediol (cf. Morrison & Boyd, Organic Chemistry, 4th ed).

The term "C₂₋₆-alkane", as used herein, is intended to include a branched or straight alkane group having from two to six carbon atoms. Typical C₂₋₆-alkane groups include, but
5 are not limited to ethane, propane, iso-propane, butane, iso-butane, pentane, hexane and the like (cf. Morrison & Boyd, Organic Chemistry, 4th ed).

The term "C₃₋₇-polyalcohol including sugars", as used herein, is intended to include a group of the formula HOCH₂(CHOH)_nCH₂OH wherein n is an integer from 1-5, and monosaccharides such as mannose, glucose (cf. Morrison & Boyd, Organic Chemistry, 4th ed).

10 The term "peptide" or "peptides", as used herein, is intended to include such polypeptides, oligopeptides, proteins, as well as homologues, analogues and derivatives thereof, which are capable of being produced by conventional recombinant DNA techniques as well as conventional synthetic methods. Such peptides include but are not limited to glucagon, hGH, insulin, aprotinin, FactorVII, TPA, FactorVIIa (NovoSeven®, available from Novo Nord-
15 isk A/S, Bagsvaerd, Denmark), FactorVIIai, FFR-FactorVIIa, heparinase, ACTH, corticotropin-releasing factor, angiotensin, calcitonin, insulin, glucagon-like peptide-1, glucagon-like peptide-2, insulin-like growth factor-1, insulin-like growth factor-2, gastric inhibitory peptide, growth hormone-releasing factor, pituitary adenylate cyclase activating peptides, secretin, enterogast-
trin, somatostatin, somatotropin, somatomedin, parathyroid hormone, thrombopoietin, erythro-
20 poietin, hypothalamic releasing factors, prolactin, thyroid stimulating hormones, endorphins, enkephalins, vasopressin, oxytocin, opioids, GIP, exendins, peptide histidine-methionine amide, helospectins, helodermin, pituitary adenylate cyclase activating peptide-related peptide, vasoactive intestinal polypeptide and analogues thereof, wherein analogues is used to designate a peptide wherein one or more amino acid residues of the parent peptide have been sub-
25 stituted by another amino acid residue and/or wherein one or more amino acid residues of the parent peptide have been deleted and/or wherein one or more amino acid residues have been added to the parent peptide. Such addition can take place either at the N-terminal end or at the C-terminal end of the parent peptide or both. Derivatives are used in the present text to designate a peptide in which one or more of the amino acid residues of the parent peptide have
30 been chemically modified, e.g. by alkylation, acylation, ester formation or amide formation or the like.

The term "salt component" as used herein, is intended to include any organic or inorganic salt, including but not limited to NaCl, KCl, NH₄Cl, CaCl₂, sodium acetate, potassium acetate, ammonium acetate, sodium citrate, potassium citrate, ammonium citrate, sodium

sulphate, potassium sulphate, ammonium sulphate, calcium acetate or mixtures thereof (cf. Remington's Pharmaceutical Sciences, Gennaro, ed., Mack Publishing Co., Easton, PA, 1990, or Remington: The Science and Practice of Pharmacy, 19th Edition (1995), or handbooks from Amersham-Pharmacia Biotech).

5 The term "a buffer" as used herein, is intended to include any buffer including but not limited to: citrate buffers, phosphate buffers, tris buffers, borate buffers, lactate buffers, gly-
cyl glycine buffers, arginine buffers, carbonate buffers, acetate buffers, glutamate buffers,
ammonium buffers, glycine buffers, alkylamine buffers, aminoethyl alcohol buffers, ethyl-
enediamine buffers, tri-ethanol amine, imidazole buffers, pyridine buffers and barbiturate
10 buffers and mixtures thereof (cf. Remington's Pharmaceutical Sciences, Gennaro, ed., Mack Publishing Co., Easton, PA, 1990, or Remington: The Science and Practice of Pharmacy, 19th Edition (1995), or handbooks from Amersham-Pharmacia Biotech).

 The choice of starting pH, buffer and ionic strength is done according to well-known techniques such as conventional test-tube methods, cf. e.g. handbooks from Amersham-
15 Pharmacia Biotech. The chromatographic ion exchange resin is chosen depending on the specific peptide to be purified and the conditions employed, such as pH, buffer, ionic strength etc., which are known to the person skilled in the art (that is, typically, pH below the isoelectric point (pI) of the peptide for cation exchange resins and pH above pI of the peptide for anion exchange resins, a sufficient buffer strength to maintain the desired pH, and a suf-
20 ficiently low ionic strength possibly induced by the salt concentration), and includes but is not limited to Sepharose resins, Sephadex resins, Streamline resins, and Source resins from Amersham-Pharmacia Biotech, HyperD resins, Trisacryl resins, and Spherosil resins from BioSeptra, TSKgel resins and Toyopearl resins from TosoHaas, Fractogel EMD resins from Merck, Poros resins from Perseptive Biosystems, Macro-Prep resins from BioRAD, Express-
25 ion resins from Whatman etc.

 The term "a solution consisting essentially of an organic modifier, water, optionally a salt component and optionally a buffer" as used herein, is intended to mean a solution con-
taining one or more organic modifiers, water, one or more salt components or no salt compo-
nent and one or more buffers or no buffer, and optionally one or more further conventional
30 components which the person skilled in the art would consider adding, according to conven-
tional ion exchange chromatography processes.

 The term "related impurities" as used herein, is intended to mean one or more impuri-
ties with a different local or overall net charge from the peptide, for instance truncated forms,
all kinds of extended forms (extra amino acids, various derivatives including esters etc.),

deamidated forms, incorrectly folded forms, forms with undesired glycosylation including sialylation, "lack of γ -carboxy glutamic acid", and others, as long as they elute before the peptide.

The term "pH-values", as used herein in connection with "at pH-values", "at the same or lower pH-values" and "at the same or higher pH-values", is intended to mean that the pH-value in step a) may be constant or may vary, typically, within 3 pH units, and subsequently, the pH-value in step b) may be at the same constant or varying pH-value as in step a), or may be at a different pH-value, which may be constant or may vary, typically, within 3 pH units. Such pH-values may typically be maintained or varied by addition of a buffer and/or an inorganic or organic acid or base, e.g. HCl, NaOH, H₂O, acetic acid, NH₃, KOH, H₂SO₄, citric acid.

The term "lower" as used herein, in connection with related impurities having a local or overall negative (or positive) net charge which is lower than the negative (or positive) net charge of the peptide, is intended to mean that the numeric value of the local or overall net charge of the related impurities is lower than the numeric value of the local or overall net charge of said peptide.

The present invention also relates to the following aspects:

Aspect 1. A cation exchange chromatography process for purifying a peptide from a mixture comprising said peptide and related impurities, comprising the steps of:

- a) eluting said related impurities of said mixture in a solution consisting essentially of an organic modifier, water, optionally a salt component and optionally a buffer, at a linear or step gradient or isocratically in salt component, and at pH-values optionally maintained with a buffer so that said peptide has a positive local or overall net charge and said related impurities have a local or overall positive net charge which is lower than the positive net charge of said peptide so as to remove said related impurities,
- b) subsequently, eluting said peptide by a step or linear change to an aqueous solvent optionally with a salt component, at the same or higher pH-values optionally maintained with a buffer.

Aspect 2. An anion exchange chromatography process for purifying a peptide from a mixture comprising said peptide and related impurities, comprising the steps of:

- a) eluting said related impurities of said mixture in a solution consisting essentially of an organic modifier, water, optionally a salt component and optionally a buffer, at a linear or step gradient or isocratically in salt component, and at pH-values optionally maintained with a buffer so that said peptide has a negative local or overall net charge and said related impuri-

ties have a local or overall negative net charge which is lower than the negative net charge of said peptide so as to remove said related impurities,

b) subsequently, eluting said peptide by a step or linear change to an aqueous solvent optionally with a salt component, at the same or lower pH-values optionally maintained with a buffer.

Aspect 3. The process according to aspect 1 or 2 wherein the ratio of organic modifier to water on a weight percent basis is from 1:99 to 99:1.

Aspect 4. The process according to any one of aspects 1-3 wherein said organic modifier is selected from C₁₋₆-alkanol, C₁₋₆-alkenol or C₁₋₆-alkynol, urea, guanidine, or C₁₋₆-alkanoic acid, C₂₋₆-glycol, or C₃₋₇-polyalcohol including sugars.

Aspect 5. The process according to any one of aspects 1-4 wherein said salt component in step a) is selected from any organic or inorganic salt, preferably NaCl, KCl, NH₄Cl, CaCl₂, sodium acetate, potassium acetate, ammonium acetate, sodium citrate, potassium citrate, ammonium citrate, sodium sulphate, potassium sulphate, ammonium sulphate, calcium acetate or mixtures thereof.

Aspect 6. The process according to any one of aspects 1-4 wherein no salt component is present in step a.

Aspect 7. The process according to any one of aspects 1-5 wherein said salt component gradient in step a) is a step or linear salt component gradient.

Aspect 8. The process according to aspects 7 wherein said salt component is present in a concentration selected from the range of 0.1 mmol/kg to 3000 mmol/kg.

Aspect 9. The process according to any one of aspects 1-8 wherein said salt component in step b) is selected from any organic or inorganic salt, preferably NaCl, KCl, NH₄Cl, CaCl₂, sodium acetate, potassium acetate, ammonium acetate, sodium citrate, potassium citrate, ammonium citrate, sodium sulphate, potassium sulphate, ammonium sulphate, calcium acetate or mixtures thereof.

Aspect 10. The process according to any one of aspects 1-9 wherein in step b) said salt component is present in a concentration selected from the range of 0.1 mmol/kg to 3000 mmol/kg.

Aspect 11. The process according to any one of aspects 1-8 wherein no salt component is present in step b.

Aspect 12. The process according to any one of aspects 1-11 wherein said buffer in step a) or b) is independently selected from citrate buffers, phosphate buffers, tris buffers, borate buffers, lactate buffers, glycyl glycine buffers, arginine buffers, carbonate buffers, ace-

tate buffers, glutamate buffers, ammonium buffers, glycin buffers, alkylamine buffers, aminoethyl alcohol buffers, ethylenediamine buffers, tri-ethanol amine, imidazole buffers, pyridine buffers and barbiturate buffers and mixtures thereof.

Aspect 13. The process according to any one of aspects 1-12 wherein said buffer in step a) is present in a concentration selected from the range of 0.1 mmol/kg to 500 mmol/kg.

Aspect 14. The process according to any one of aspects 1-13 wherein said buffer in step b) is present in a concentration selected from the range of 0.1 mmol/kg to 1000 mmol/kg.

Aspect 15. The process according to any one of aspects 1-11 wherein no buffer is present in step a).

Aspect 16. The process according to any one of aspects 1-11 wherein no buffer is present in step b).

Aspect 17. A method for isolating a peptide, the method including purification of a peptide from a mixture containing said peptide and related impurities via a cation exchange chromatography process, the cation exchange chromatography process comprising the steps of:

a) eluting said related impurities of said mixture in a solution consisting essentially of an organic modifier, water, optionally a salt component and optionally a buffer, at a linear or step salt component gradient or isocratically, and at pH-values optionally maintained with a buffer so that said peptide has a positive local or overall net charge and said related impurities have a local or overall positive net charge which is lower than the positive net charge of said peptide so as to remove said related impurities,

b) subsequently, eluting said peptide by a step or linear change to an aqueous solvent optionally with a salt component, at the same or higher pH-values optionally maintained with a buffer;

and subsequently, if necessary, subjecting to analytical tests and/or further purification, and isolating said peptide in a conventional manner.

Aspect 18. A method for isolating a peptide, the method including purification of a peptide from a mixture containing said peptide and related impurities via an anion exchange chromatography process, the anion exchange chromatography process comprising the steps of:

a) eluting said related impurities of said mixture in a solution consisting essentially of an organic modifier, water, optionally a salt component and optionally a buffer, at

a linear or step salt component gradient or isocratically, and at pH-values optionally maintained with a buffer so that said peptide has a negative local or overall net charge and said related impurities have a local or overall negative net charge which is lower than the negative net charge of said peptide so as to remove said related impurities,

b) subsequently, eluting said peptide by a step or linear change to an aqueous solvent optionally with a salt component, at the same or lower pH-values optionally maintained with a buffer;

and subsequently, if necessary, subjecting to analytical tests and/or further purification, and isolating said peptide in a conventional manner.

Aspect 19. The process or method according to any one of aspects 1-18 wherein said peptide to be purified is selected from polypeptides, oligopeptides, proteins, receptors, vira, as well as homologues, analogues and derivatives thereof, preferably glucagon, hGH, insulin, aprotinin, FVII, TPA, FVIIa, FFR-FVIIa, heparinase, ACTH, Heparin Binding Protein, corticotropin-releasing factor, angiotensin, calcitonin, insulin, glucagon-like peptide-1, glucagon-like peptide-2, insulin-like growth factor-1, insulin-like growth factor-2, fibroblast growth factors, gastric inhibitory peptide, growth hormone-releasing factor, pituitary adenylate cyclase activating peptides, secretin, enterogastrin, somatostatin, somatotropin, somatomedin, parathyroid hormone, thrombopoietin, erythropoietin, hypothalamic releasing factors, prolactin, thyroid stimulating hormones, endorphins, enkephalins, vasopressin, oxytocin, opioids, DPP IV, interleukins, immunoglobulins, complement inhibitors, serpin protease inhibitors, cytokines, cytokine receptors, PDGF, tumor necrosis factors, tumor necrosis factors receptors, growth factors, GIP, exendins, peptide histidine-methionine amide, helospectins, helodermin, pituitary adenylate cyclase activating peptide-related peptide, vasoactive intestinal polypeptide and analogues as well as derivatives thereof, more preferably glucagon, hGH, insulin, aprotinin, FVII, FVIIa, FFR-FVIIa, heparinase, glucagon-like peptide-1, glucagon-like peptide-2 and analogues as well as derivatives thereof, such as Arg³⁴GLP-1₍₇₋₃₇₎, human insulin, and B28IsoAsp insulin.

Examples

The present invention is further illustrated by the following examples which, however, are not to be construed as limiting the scope of protection. The features disclosed in the foregoing description and in the following examples may, both separately and in any combination thereof, be material for realising the invention in diverse forms thereof.

Example 1:

Arg³⁴GLP-1₍₇₋₃₇₎ was expressed in yeast (*Sacch. cerevisiae*) by conventional recombinant DNA technology e.g as described in WO 98/08871. Arg³⁴GLP-1₍₇₋₃₇₎ fermentation broth was purified by a conventional reverse phase chromatography capture step, and subsequently precipitated at the pI (isoelectric point) of Arg³⁴GLP-1₍₇₋₃₇₎. 2 g of the precipitate containing Arg³⁴GLP-1₍₇₋₃₇₎ and the truncated form missing a histidine and an alanine residue, Arg³⁴GLP-1₍₉₋₃₇₎, as one of several impurities was suspended in 100 ml water and dissolved by pH adjustment to 8.2. The resulting mixture was adjusted to pH 3.4 and filtered. 21 ml of the filtrate was applied to a 20 ml Source 30S (Amersham Pharmacia Biotech) column equilibrated with 100 ml 20 mmol/kg citric acid, 75 mmol/kg KCl, 45 % w/w ethanol, pH 3.5. The truncated form was eluted/washed off by a step gradient of 60 ml 20 mmol/kg citric acid, 87.5 mmol/kg KCl, 45 % w/w ethanol, pH 3.5. The target peptide, Arg³⁴GLP-1₍₇₋₃₇₎, was eluted in a single peak by a step gradient of 100 ml 200 mmol/kg Tris-hydroxymethyl aminomethane, pH 8.5. A chromatogram is shown in Figure 1.

RP-HPLC analysis for identification/verification of collected peaks was carried out on a C₁₈-substituted 120 Å silica (YMC) 4.0×250 mm column with 5 µm particles. Buffer A consisted of 0.15 M (NH₄)₂SO₄ in 7.8 % acetonitrile, pH 2.5, and buffer B contained 63.4 % acetonitrile. Linear gradients from 37-41 % B in 12 min followed by 41-100 % B in 15 min were run at a flow rate of 1 ml/min. The chromatographic temperature was kept at 60°C and UV detection was performed at 214 nm. Analytical results were:

	Arg ³⁴ GLP-1 ₍₇₋₃₇₎ content	Arg ³⁴ GLP-1 ₍₉₋₃₇₎ content
Sample for application	48%	18%
Wash containing ethanol	1%	76%
Aqueous eluate	65%	1%

Chromatograms of the sample for application and the eluate is shown in Figures 2 and 3, respectively. The analytical results show a selective removal of the truncated form by the wash step containing ethanol and a high reduction of the truncated form in the aqueous eluate by employment of the cation exchange chromatography method.

Example 2:

Arg³⁴GLP-1₍₇₋₃₇₎ fermentation broth was purified by cation exchange chromatography and precipitated as described in Example 1.

2 g of the precipitate containing Arg³⁴GLP-1₍₇₋₃₇₎ and the truncated form, Arg³⁴GLP-1₍₉₋₃₇₎, as one impurity was suspended and dissolved in 100 ml 20 mmol/kg glycine, pH 9.0 resulting in a final pH of 8.4. The resulting mixture was adjusted to pH 3.5 and filtered. 52 ml of the filtrate was applied to a 20 ml Source 30S (Amersham Pharmacia Biotech) column equilibrated with 60 ml 20 mmol/kg citric acid, 75 mmol/kg KCl, 45 % w/w ethanol, pH 3.5. The truncated form was eluted/washed off by a step gradient of 60 ml 20 mmol/kg citric acid, 87.5 mmol/kg KCl, 45 % w/w ethanol, pH 3.5. The target peptide, Arg³⁴GLP-1₍₇₋₃₇₎, was eluted in a single peak by a step gradient of 100 ml 200 mmol/kg glycine, pH 9.0. RP-HPLC analysis for identification/verification of collected peaks was carried out as described in Example 1.

The analytical results show a selective removal of the truncated form by the wash step containing ethanol and a high reduction of the truncated form in the aqueous eluate by employment of the cation exchange chromatography method.

Example 3:

Arg³⁴GLP-1₍₇₋₃₇₎ fermentation broth was purified by a conventional cation exchange chromatography capture step followed by a conventional RP-HPLC purification step.

4 volumes of water was added to the RP-HPLC pool containing Arg³⁴GLP-1₍₇₋₃₇₎ and the truncated form, Arg³⁴GLP-1₍₉₋₃₇₎, as an impurity. 175 ml of the resulting solution was adjusted to pH 3.5 and applied to a 20 ml Source 30S (Amersham Pharmacia Biotech) column equilibrated with 100 ml 20 mmol/kg citric acid, 75 mmol/kg KCl, 45 % w/w ethanol, pH 3.5. The

column was washed with 20 ml equilibration solution, and the truncated form was eluted/washed off by a linear gradient from 75 to 100 mmol/kg KCl (20 mmol/kg citric acid, 45 % w/w ethanol, pH 3.5). The target peptide, Arg³⁴GLP-1₍₇₋₃₇₎, was eluted in a single peak by a step gradient of 100 ml 100 mmol/kg Na₂CO₃, pH 9.5. A chromatogram is shown in Figure 4.

Example 4:

Arg³⁴GLP-1₍₇₋₃₇₎ was expressed, captured by cation exchange, and purified by RP-HPLC as described in Example 3.

1 volume of water was added to the RP-HPLC pool containing Arg³⁴GLP-1₍₇₋₃₇₎ and the truncated form, Arg³⁴GLP-1₍₉₋₃₇₎, as an impurity. 86 ml of the resulting solution was adjusted to pH 3.5 and applied to a 20 ml Source 30S (Amersham Pharmacia Biotech) column equilibrated with 100 ml 20 mmol/kg citric acid, 75 mmol/kg KCl, 45 % w/w ethanol, pH 3.5. The column was washed with 20 ml equilibration solution, and the truncated form was eluted/washed off by a linear gradient from 75 to 100 mmol/kg KCl (20 mmol/kg citric acid, 45 % w/w ethanol, pH 3.5). The target peptide, Arg³⁴GLP-1₍₇₋₃₇₎, was eluted by a step gradient of 100 ml 100 mmol/kg H₃BO₃, 100 mmol/kg NaCl, pH 9.5.

Example 5:

Arg³⁴GLP-1₍₇₋₃₇₎ was isolated from the fermentation broth by conventional reverse phase chromatography and precipitated as described in Example 1.

10 g of the precipitate containing Arg³⁴GLP-1₍₇₋₃₇₎ and the truncated form, Arg³⁴GLP-1₍₉₋₃₇₎, as one of several impurities was suspended in 500 ml water and dissolved by pH adjustment to 8.3 to a Arg³⁴GLP-1₍₇₋₃₇₎ concentration of approximately 1.6 mg/ml. 5 ml of the resulting solution was adjusted to pH 3.5 and applied to a 20 ml Source 30S (Amersham Pharmacia Biotech) column equilibrated with 60 ml 0.42 % w/w citric acid, 34 % w/w ethanol, pH 3.5. The truncated form was eluted/washed off by a linear gradient from 0 to 1.29 % w/w KCl (0.42 % w/w citric acid, 34 % w/w ethanol, pH 3.5). The target peptide, Arg³⁴GLP-1₍₇₋₃₇₎, was eluted in a single peak by a step gradient of 100 ml 200 mmol/kg glycine, pH 9.5. A chromatogram is shown in Figure 5.

Example 6:

Arg³⁴GLP-1₍₇₋₃₇₎ was isolated from the fermentation broth by conventional reverse phase chromatography and precipitated as described in Example 1.

10 g of the precipitate containing Arg³⁴GLP-1₍₇₋₃₇₎ and the truncated form, Arg³⁴GLP-1₍₉₋₃₇₎, as one of several impurities was suspended in 500 ml water and dissolved by pH adjustment to 8.3 to a Arg³⁴GLP-1₍₇₋₃₇₎ concentration of approximately 1.6 mg/ml. 5 ml of the resulting solution was adjusted to pH 3.2 and applied to a 20 ml Source 30S (Amersham Pharmacia Bio-
5 tech) column equilibrated with 60 ml 0.42 % w/w citric acid, 29 % w/w ethanol, pH 3.5. The truncated form was eluted/washed off by a linear gradient from 0 to 1.96 % w/w KCl (0.42 % w/w citric acid, 29 % w/w ethanol, pH 3.5). The target peptide, Arg³⁴GLP-1₍₇₋₃₇₎, was eluted by a step gradient of 100 ml 200 mmol/kg glycine, pH 9.5.

10 Example 7:

Arg³⁴GLP-1₍₇₋₃₇₎ was isolated from the fermentation broth by conventional reverse phase chromatography and precipitated as described in Example 1.

10 g of the precipitate containing Arg³⁴GLP-1₍₇₋₃₇₎ and the truncated form, Arg³⁴GLP-1₍₉₋₃₇₎, as one of several impurities was suspended in 500 ml water and dissolved by pH adjustment to
15 8.3 to a Arg³⁴GLP-1₍₇₋₃₇₎ concentration of approximately 1.6 mg/ml. 5 ml of the resulting solution was adjusted to pH 3.5 and applied to a 20 ml Source 30S (Amersham Pharmacia Bio- tech) column equilibrated with 60 ml 0.42 % w/w citric acid, 51 % w/w ethanol, pH 3.5. The truncated form was eluted/washed off by a linear gradient from 0 to 1.00 % w/w KCl (0.42 % w/w citric acid, 51 % w/w ethanol, pH 3.5). The target peptide, Arg³⁴GLP-1₍₇₋₃₇₎, was eluted by
20 a step gradient of 100 ml 200 mmol/kg glycine, pH 9.5.

Example 8:

Arg³⁴GLP-1₍₇₋₃₇₎ was isolated from the fermentation broth by conventional reverse phase chromatography and precipitated as described in Example 1.

25 10 g of the precipitate containing Arg³⁴GLP-1₍₇₋₃₇₎ and the truncated form, Arg³⁴GLP-1₍₉₋₃₇₎, as one of several impurities was suspended in 500 ml water and dissolved by pH adjustment to 8.3 to a Arg³⁴GLP-1₍₇₋₃₇₎ concentration of approximately 1.6 mg/ml. 5 ml of the resulting solution was adjusted to pH 3.5 and applied to a 20 ml Source 30S (Amersham Pharmacia Bio- tech) column equilibrated with 60 ml 0.42 % w/w citric acid, 71 % w/w ethanol, pH 3.5. The
30 truncated form was eluted/washed off by a linear gradient from 0 to 0.48 % w/w KCl (0.42 % w/w citric acid, 71 % w/w ethanol, pH 3.5). The target peptide, Arg³⁴GLP-1₍₇₋₃₇₎, was eluted by a step gradient of 100 ml 200 mmol/kg glycine, pH 9.5.

Example 9:

Arg³⁴GLP-1₍₇₋₃₇₎ was isolated from the fermentation broth by conventional reverse phase chromatography and precipitated as described in Example 1.

10 g of the precipitate containing Arg³⁴GLP-1₍₇₋₃₇₎ and the truncated form, Arg³⁴GLP-1₍₉₋₃₇₎, as
5 one of several impurities was suspended in 500 ml water and dissolved by pH adjustment to 8.3 to a Arg³⁴GLP-1₍₇₋₃₇₎ concentration of approximately 1.6 mg/ml. 5 ml of the resulting solution was adjusted to pH 3.5 and applied to a 20 ml Source 30S (Amersham Pharmacia Biotech) column equilibrated with 60 ml 0.42 % w/w citric acid, 40 % w/w 2-propanol, pH 3.5. The truncated form was eluted/washed off by a linear gradient from 0 to 0.61 % w/w KCl
10 (0.42 % w/w citric acid, 40 % w/w 2-propanol, pH 3.5). The target peptide, Arg³⁴GLP-1₍₇₋₃₇₎, was eluted in a single peak by a step gradient of 100 ml 200 mmol/kg glycine, pH 9.5. A chromatogram is shown in Figure 6.

Example 10:

15 Arg³⁴GLP-1₍₇₋₃₇₎ was isolated from the fermentation broth by conventional reverse phase chromatography and precipitated as described in Example 1.
10 g of the precipitate containing Arg³⁴GLP-1₍₇₋₃₇₎ and the truncated form, Arg³⁴GLP-1₍₉₋₃₇₎, as one of several impurities was suspended in 500 ml water and dissolved by pH adjustment to 8.3 to a Arg³⁴GLP-1₍₇₋₃₇₎ concentration of approximately 1.6 mg/ml. 5 ml of the resulting solution was adjusted to pH 3.5 and applied to a 8 ml Poros 50 HS (PE Biosystems) column
20 equilibrated with 24 ml 0.42 % w/w citric acid, 51 % w/w ethanol, pH 3.5. The truncated form was eluted/washed off by a linear gradient from 0 to 1.34 % w/w KCl (0.42 % w/w citric acid, 51 % w/w ethanol, pH 3.5). The target peptide, Arg³⁴GLP-1₍₇₋₃₇₎, was eluted by a step gradient of 40 ml 200 mmol/kg glycine, pH 9.5. A chromatogram is shown in Figure 7.

25

Example 11:

Arg³⁴GLP-1₍₇₋₃₇₎ was isolated from the fermentation broth by conventional reverse phase chromatography and precipitated as described in Example 1.

10 g of the precipitate containing Arg³⁴GLP-1₍₇₋₃₇₎ and the truncated form, Arg³⁴GLP-1₍₉₋₃₇₎, as
30 one of several impurities was suspended in 500 ml water and dissolved by pH adjustment to 8.3 to a Arg³⁴GLP-1₍₇₋₃₇₎ concentration of approximately 1.6 mg/ml. 5 ml of the resulting solution was adjusted to pH 3.5 and applied to a 8 ml Poros 50 HS (PE Biosystems) column equilibrated with 24 ml 0.42 % w/w citric acid, 40 % w/w 2-propanol, pH 3.5. The truncated form was eluted/washed off by a linear gradient from 0 to 1.34 % w/w KCl (0.42 % w/w citric

acid, 40 % w/w 2-propanol, pH 3.5). The target peptide, Arg³⁴GLP-1₍₇₋₃₇₎, was eluted by a step gradient of 40 ml 200 mmol/kg glycine, pH 9.5. A chromatogram is shown in Figure 8.

Example 12:

5 Arg³⁴GLP-1₍₇₋₃₇₎ was isolated from the fermentation broth by conventional reverse phase chromatography and precipitated as described in Example 1.
10 g of the precipitate containing Arg³⁴GLP-1₍₇₋₃₇₎ and the truncated form, Arg³⁴GLP-1₍₈₋₃₇₎, as one of several impurities was suspended in 500 ml water and dissolved by pH adjustment to 8.3 to a Arg³⁴GLP-1₍₇₋₃₇₎ concentration of approximately 1.6 mg/ml. 5 ml of the resulting solution was adjusted to pH 3.5 and applied to a 20 ml Source 30S (Amersham Pharmacia Bio-
10 tech) column equilibrated with 60 ml 0.42 % w/w citric acid, 40 % w/w 2-methyl-2,4-pentanediol, pH 3.5. The truncated form was eluted/washed off by a linear gradient from 0 to 0.60 % w/w KCl (0.42 % w/w citric acid, 40 % w/w 2-methyl-2,4-pentanediol, pH 3.5). The target peptide, Arg³⁴GLP-1₍₇₋₃₇₎, was eluted in a single peak by a step gradient of 100 ml 200
15 mmol/kg glycine, pH 9.5. A chromatogram is shown in Figure 9.

Example 13:

 A mixture of 7.7 mg/ml human insulin and 0.8 mg/ml human insulin ethyl ester (B30) was obtained by conventional methods as described elsewhere (cf. I. Møllerup, S.W. Jensen, P. Larsen, O. Schou, L. Snel: Insulin, Purification, in M.C. Flickinger, S.W. Drew: Encyclopedia of Bioprocess Technology: Fermentation, Biocatalysis, and Bioseparation, John Wiley & Sons, 1999). The mixture contained 4 mmol/l EDTA, 16 % w/w ethanol, pH 7.5. 2 ml of the mixture was applied to a 20 ml TSK-Gel Q-5PW (TosoHaas) column equilibrated with 40 ml 0.15 % w/w triethanolamine, 42.5 % w/w ethanol, pH 7.5. The human insulin ethyl ester impurity was eluted/washed off by a linear gradient from 0 to 1.14 % w/w sodium citrate tri-hydrate (0.15 % w/w triethanolamine, 42.5 % w/w ethanol, pH 7.5). The target protein,
25 human insulin, was eluted in a single peak by a step gradient of 60 ml 2.72 % w/w sodium citrate tri-hydrate, 0.15 % w/w triethanolamine, pH 7.5. A chromatogram is shown in Figure 10.

30

Example 14:

 A mixture of human insulin and human insulin ethyl ester (B30) was obtained as described in Example 13. 2 ml of the mixture was applied to a 20 ml TSK-Gel Q-5PW (Toso-Haas) column equilibrated with 40 ml 0.15 % w/w triethanolamine, 42.5 % w/w ethanol, pH

7.5. The human insulin ethyl ester impurity was eluted/washed off by a linear gradient from 0 to 0.90 % w/w sodium citrate tri-hydrate (0.15 % w/w triethanolamine, 42.5 % w/w ethanol, pH 7.5). The target protein, human insulin, was eluted in a single peak by a step gradient of 60 ml 100 mmol/l citric acid, pH 3. A chromatogram is shown in Figure 11.

5

Example 15:

A mixture of human insulin and human insulin ethyl ester (B30) was obtained as described in Example 13. 2 ml of the mixture was applied to a 20 ml TSK-Gel Q-5PW (Toso-Haas) column equilibrated with 40 ml 0.15 % w/w triethanolamine, 71 % w/w ethanol, pH 7.5.

10 The human insulin ethyl ester impurity was eluted/washed off by a linear gradient from 0 to 1.63 % w/w sodium citrate tri-hydrate (0.15 % w/w triethanolamine, 71 % w/w ethanol, pH 7.5). The target protein, human insulin, was eluted in a single peak by a step gradient of 60 ml 2.72 % w/w sodium citrate tri-hydrate, 0.15 % w/w triethanolamine, pH 7.5.

15 Example 16:

A mixture of 9.0 mg/ml human insulin and 0.6 mg/ml human insulin ethyl ester (B30) was obtained as described in Example 13. The mixture contained 4 mmol/l EDTA, pH 7.5 with a human insulin concentration of 9 mg/ml. 2 ml of the mixture was applied to a 20 ml TSK-Gel Q-5PW (TosoHaas) column equilibrated with 40 ml 0.15 % w/w triethanolamine, 81
20 % w/w ethanol, pH 7.5. The human insulin ethyl ester impurity was eluted/washed off by a linear gradient from 0 to 2.18 % w/w sodium citrate tri-hydrate (0.15 % w/w triethanolamine, 81 % w/w ethanol, pH 7.5). The target protein, human insulin, was eluted in a single peak by a step gradient of 60 ml 2.72 % w/w sodium citrate tri-hydrate, 0.15 % w/w triethanolamine, pH 7.5. A chromatogram is shown in Figure 12.

25

Example 17:

A mixture of human insulin and human insulin ethyl ester (B30) was obtained as described in Example 16. 2 ml of the mixture was applied to a 20 ml TSK-Gel Q-5PW (Toso-Haas) column equilibrated with 40 ml 0.15 % w/w triethanolamine, 51 % w/w ethanol, pH 7.5.

30 The human insulin ethyl ester impurity was eluted/washed off by a linear gradient from 0 to 1.09 % w/w sodium citrate tri-hydrate (0.15 % w/w triethanolamine, 51 % w/w ethanol, pH 7.5). The target protein, human insulin, was eluted in a single peak by a step gradient of 60 ml 2.72 % w/w sodium citrate tri-hydrate, 0.15 % w/w triethanolamine, pH 7.5.

CLAIMS

1. A cation exchange chromatography process for purifying a peptide from a mixture comprising said peptide and related impurities, comprising the steps of:
 - 5 a) eluting said related impurities of said mixture in a solution comprising an organic modifier, water, optionally a salt component and optionally a buffer, at a linear or step gradient or isocratically in salt component, and at pH-values optionally maintained with a buffer so that said peptide has a positive local or overall net charge and said related impurities have a local or overall positive net charge which is lower than the positive net charge of said peptide so
10 as to remove said related impurities,
 - b) subsequently, eluting said peptide by a step or linear change to an aqueous solvent optionally with a salt component, at the same or higher pH-values optionally maintained with a buffer.
- 15 2. An anion exchange chromatography process for purifying a peptide from a mixture comprising said peptide and related impurities, comprising the steps of:
 - a) eluting said related impurities of said mixture in a solution comprising an organic modifier, water, optionally a salt component and optionally a buffer, at a linear or step gradient or isocratically in salt component, and at pH-values optionally maintained with a buffer so that
20 said peptide has a negative local or overall net charge and said related impurities have a local or overall negative net charge which is lower than the negative net charge of said peptide so as to remove said related impurities,
 - b) subsequently, eluting said peptide by a step or linear change to an aqueous solvent optionally with a salt component, at the same or lower pH-values optionally maintained with a
25 buffer.
3. An industrial method for producing a pure peptide, the method including a cation exchange chromatography process for purifying a peptide from a mixture comprising said peptide and related impurities, comprising the steps of:
 - 30 a) eluting said related impurities of said mixture in a solution consisting essentially of an organic modifier, water, optionally a salt component and optionally a buffer, at a linear or step gradient or isocratically in salt component, and at pH-values optionally maintained with a buffer so that said peptide has a positive local or overall net charge and said related impuri-

ties have a local or overall positive net charge which is lower than the positive net charge of said peptide so as to remove said related impurities,

b) subsequently, eluting said peptide by a step or linear change to an aqueous solvent optionally with a salt component, at the same or higher pH-values optionally maintained with a buffer.

4. An industrial method for producing a pure peptide, the method including an anion exchange chromatography process for purifying a peptide from a mixture comprising said peptide and related impurities, comprising the steps of:

a) eluting said related impurities of said mixture in a solution consisting essentially of an organic modifier, water, optionally a salt component and optionally a buffer, at a linear or step gradient or isocratically in salt component, and at pH-values optionally maintained with a buffer so that said peptide has a negative local or overall net charge and said related impurities have a local or overall negative net charge which is lower than the negative net charge of said peptide so as to remove said related impurities,

b) subsequently, eluting said peptide by a step or linear change to an aqueous solvent optionally with a salt component, at the same or lower pH-values optionally maintained with a buffer.

5. A method for isolating a peptide, the method including purification of a peptide from a mixture containing said peptide and related impurities via a cation exchange chromatography process, the cation exchange chromatography process comprising the steps of:

a) eluting said related impurities of said mixture in a solution comprising an organic modifier, water, optionally a salt component and optionally a buffer, at a linear or step salt component gradient or isocratically, and at pH-values optionally maintained with a buffer so that said peptide has a positive local or overall net charge and said related impurities have a local or overall positive net charge which is lower than the positive net charge of said peptide so as to remove said related impurities,

b) subsequently, eluting said peptide by a step or linear change to an aqueous solvent optionally with a salt component, at the same or higher pH-values optionally maintained with a buffer;

and subsequently, if necessary, subjecting to analytical tests and/or further purification, and isolating said peptide in a conventional manner.

6. A method for isolating a peptide, the method including purification of a peptide from a mixture containing said peptide and related impurities via an anion exchange chromatography process, the anion exchange chromatography process comprising the steps of:

5 a) eluting said related impurities of said mixture in a solution comprising an organic modifier, water, optionally a salt component and optionally a buffer, at a linear or step salt component gradient or isocratically, and at pH-values optionally maintained with a buffer so that said peptide has a negative local or overall net charge and said related impurities have a local or overall negative net charge which is lower than the negative net charge of said peptide so as to remove said related impurities,

10 b) subsequently, eluting said peptide by a step or linear change to an aqueous solvent optionally with a salt component, at the same or lower pH-values optionally maintained with a buffer;

and subsequently, if necessary, subjecting to analytical tests and/or further purification, and isolating said peptide in a conventional manner.

15 7. The process or method according to any one of claims 1-6 wherein said peptide to be purified is selected from polypeptides, oligopeptides, proteins, receptors, vira, as well as homologues, analogues and derivatives thereof.


20 8. The process or method according to any one of claims 1-7 wherein said peptide to be purified is selected from glucagon, hGH, insulin, FactorVII, FactorVIIa, FactorVIIai, FFR-FactorVIIa, glucagon-like peptide-1, glucagon-like peptide-2 and analogues as well as derivatives thereof.

25 9. The process or method according to any one of claims 1-8 wherein the ratio of organic modifier to water on a weight percent basis is from 1:99 to 99:1.

10. The process or method according to any one of claims 1-9 wherein said organic modifier is selected from C₁₋₆-alkanol, C₁₋₆-alkenol or C₁₋₆-alkynol, urea, guanidine, or C₁₋₆-alkanoic acid,

30 C₂₋₆-glycol, or C₃₋₇-polyalcohol including sugars.


1/8



Chromatogram of Example 1.

Fig. 1.


2/8



Analytical chromatogram of Example 1. Sample for application.

Fig. 2


3/8



Analytical chromatogram of Example 1. Eluate.

Fig. 3


4/8



Chromatogram of Example 3.


Fig. 4

5/8



Chromatogram of Example 5.


Fig. 5



Chromatogram of Example 9.


Fig. 6

6/8



Chromatogram of Example 10.


Fig. 7




Chromatogram of Example 11.

Fig. 8

7/8




Chromatogram of Example 12.

Fig. 9

Chromatogram of Example 13


Fig. 10

8/8



Chromatogram of Example 14.

Fig. 11



Chromatogram of Example 16.

Fig. 12

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 00/00112

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07K 1/18, C07K 14/605, C07K 14/62

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

MEDLINE, BIOSIS, EMBASE, SCISEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 3907676 A (KLAUS HOLGER JORGENSEN), 23 Sept 1975 (23.09.75), see columns 4-5, fig. 1 and claims --	2,4,6-10
X	EP 0849277 A2 (HOECHST AKTIENGESELLSCHAFT), 24 June 1998 (24.06.98), see page 3, line 52 - page 4, line 14 and claims --	1,3,5,7-10
X	US 5101013 A (MICHAEL DÖRSCHUG ET AL), 31 March 1992 (31.03.92), see column 2, lines 50-68, column 3, lines 33-37 and claims --	1,3,5,7-10

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

6 July 2000

Date of mailing of the international search report

21-07-2000

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Carl-Olof Gustafsson/EÖ

Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 00/00112

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0207727 A2 (ELI LILLY AND COMPANY), 7 January 1987 (07.01.87), see page 10 and claims --	2,4,6-10
X	WO 9000176 A1 (BIOBRAS BIOQUIMICA DO BRASIL S.A.), 11 January 1990 (11.01.90), see examples and claims 1 and 5 --	2,4,6-10
X	WO 9000177 A1 (BIOBRAS BIOQUIMICA DO BRASIL S.A.), 11 January 1990 (11.01.90), see examples --	2,4,6-10
X	US 4129560 A (MANFRED ZOLTOBROCKI), 12 December 1978 (12.12.78), see the examples --	2,4,6-10
X	STN International, file BIOSIS, BIOSIS accession no. PREV198274065982, Dizdaroglu M et al: "Separation of peptides by high performance liquid chromatography on a weak anion exchange bonded phase"; & Journal of Chromatography, 1982, vol. 237, pages 417-428	2,4,6-10
A	 --	1,3,5
A	STN International, file BIOSIS, BIOSIS accession no. PREV198783093472, Stadalius M A et al: "Predicting bandwidth in the high-performance liquid chromatographic separation of large biomolecules II. A general model for the four common high-performance liquid chromatography methods"; & Journal of Chromatography, 1987, vol. 387, pages 21-40 -- -----	1-10

INTERNATIONAL SEARCH REPORT
Information on patent family members

02/12/99

International application No.

PCT/DK 00/00112

Patent document cited in search report			Publication date	Patent family member(s)	Publication date
US	3907676	A	23/09/75	NONE	
EP	0849277	A2	24/06/98	AU 4842197 A CA 2225178 A DE 19652713 A JP 10182700 A US 5977297 A	25/06/98 18/06/98 25/06/98 07/07/98 02/11/99
US	5101013	A	31/03/92	AT 96447 T AU 609170 B AU 2059188 A CA 1340237 A DE 3726655 A DE 3885214 D DK 447688 A EP 0305760 A,B SE 0305760 T3 ES 2047007 T FI 91875 B,C FI 883708 A IE 61557 B IL 87385 A JP 1086896 A JP 2587867 B KR 129539 B NO 175004 B,C NO 883554 D NZ 225746 A PH 26874 A PT 88230 A,B	15/11/93 26/04/91 16/02/89 15/12/98 23/02/89 00/00/00 12/02/89 08/03/89 16/02/94 13/05/94 12/02/89 16/11/94 18/08/93 31/03/89 05/03/97 04/04/98 09/05/94 00/00/00 27/11/90 16/11/92 30/06/89
EP	0207727	A2	07/01/87	AU 587835 B AU 5934286 A CA 1284000 A DK 301786 A JP 1992073 C JP 7020998 B JP 62005998 A US 4617376 A	31/08/89 08/01/87 07/05/91 02/01/87 22/11/95 08/03/95 12/01/87 14/10/86
WO	9000176	A1	11/01/90	NONE	
WO	9000177	A1	11/01/90	NONE	

INTERNATIONAL SEARCH REPORT

Information on patent family members

02/12/99

International application No.

PCT/DK 00/00112

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4129560 A	12/12/78	AT 352922 B	10/10/79
		AT 466377 A	15/03/79
		AU 509110 B	17/04/80
		AU 2660477 A	04/01/79
		BE 856385 A	02/01/78
		CA 1086308 A	23/09/80
		CH 626051 A	30/10/81
		DE 2629568 A,B,C	12/01/78
		DK 149201 B,C	10/03/86
		DK 293277 A	02/01/78
		ES 460099 A	01/05/78
		FI 61490 B,C	30/04/82
		FI 772023 A	02/01/78
		FR 2356630 A,B	27/01/78
		GB 1582056 A	31/12/80
		GR 78333 A	26/09/84
		IE 44766 B	24/03/82
		IT 1080658 B	16/05/85
		JP 1359899 C	30/01/87
		JP 53005101 A	18/01/78
		JP 61026560 B	20/06/86
		NL 188804 B,C	06/05/92
		NL 7707037 A	03/01/78
		NO 145692 B	01/02/82
		NO 772318 A	03/01/78
		NZ 184516 A	25/10/79
		PT 66751 A,B	01/07/77
		SE 440507 B	05/08/85
		SE 7707612 A	02/01/78
		ZA 7703964 A	30/05/78